NCT02721043 2021-01-11
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
Clinical Trials
4 trialsNCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT00046735 2019-11-18
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
Celgene
Phase 1 Completed
NCT01750983 2019-02-25
Ipilimumab and Lenalidomide in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed